Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.
Alvotech and JAMP Pharma have entered into an exclusive partnership to commercialize five key biosimilars in the Canadian market. According to Alvotech, the current market value of the branded sales for these biosimilars is estimated to exceed $2bn annually.
Privately-owned JAMP Pharma will have exclusive rights to commercialize Alvotech’s biosimilars in Canada, while Alvotech will be responsible for full...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
